Vlp-based monovalent ebola vaccines and methods of making and using same
AssigneeChildren's Hospital Medical Center
InventorsXuemin Chen, Karnail Singh, Paul Spearman
Life of this patent
Estimating the term…
Abstract
Disclosed herein are virus-like particle (VLP)-based monovalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and a single Ebola glycoprotein selected from either a Zaire (EBOV) glycoprotein or a Sudan (SUDV) glycoprotein. The Ebola glycoprotein may be incorporated into the surface of the spherical Gag core, wherein said VLP-based vaccine presents a single Ebola glycoprotein antigen.
Claims26
A virus-like particle (VLP)-based monovalent vaccine composition comprising a spherical retroviral Group-specific Antigen (“Gag”) protein core and a single Ebola glycoprotein selected from either a Zaire (EBOV) glycoprotein or a Sudan (SUDV) glycoprotein, wherein said Ebola glycoprotein is incorporated into the surface of said spherical Gag core, wherein said VLP-based vaccine presents a single Ebola glycoprotein antigen.
A composition comprising a cell line comprising a first plasmid containing a sequence encoding for a gag protein under the control of an inducible promoter, and a second plasmid containing a sequence encoding for an Ebola glycoprotein under the control of an inducible promoter.
Dependencies are inferred from the claim text.